Video-oculography and Parkinson's Disease

  • End date
    Jan 30, 2029
  • participants needed
  • sponsor
    Association de Recherche Bibliographique pour les Neurosciences
Updated on 25 January 2022
ct scan
movement disorder
antiparkinsonian agents


This study aims to study, in patient with Parkinson's disease, mild to moderate stage (according to Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease, Postuma et al., 2015):

  • the evolution of oculomotricity markers over time.
  • the correlation between neurological evaluations (motor and non-motor scores), neuropsychological evaluations (cognitive disorders) and oculomotricity evaluation, over a follow-up period of 7 years.
  • the impact of antiparkinsonian drugs on the evolution of oculomotricity assessment by video-oculography.
  • the value of oculomotricity assessment by video-oculography as an evolutionary marker of the disease.

Condition Parkinson Disease, Idiopathic
Treatment Video-oculography / Neuropsychological evaluations
Clinical Study IdentifierNCT04731246
SponsorAssociation de Recherche Bibliographique pour les Neurosciences
Last Modified on25 January 2022


Yes No Not Sure

Inclusion Criteria

Male or Female
Clinically defined idiopathic Parkinson's Disease (PD)
Brain MRI performed in routine care in the 12 months preceding inclusion
Cerebral DaTSCAN or cerebral PET with F-DOPA, performed as routine care before inclusion (no time limit), confirming presynaptic dopaminergic denervation
Hoehn & Yahr score: 1 to 3
Normal clinical examination of oculomotricity (slight impairment of smooth pursuit accepted)
Neuro-cognitive disorders: absent or minor (according to DSM5)
Sufficient written and oral expression in French
Covered by a health insurance system
Written informed consent signed by the patient
Presence of a caregiver

Exclusion Criteria

Psychiatric comorbidity (except anxiety or mild to moderate depression)
Neurological comorbidity, if significant
Brain MRI showing
significant cerebrovascular pathology (Fazekas I admitted)
another brain disease, including stroke
Major cognitive impairment
Absolute exclusion criteria and "Red flags" of the 2015 criteria orienting towards another degenerative pathology of the extrapyramidal system
Cerebellar syndrome
Vertical oculomotricity disorders on clinical examination
Motor symptoms restricted to the lower limbs
Bilateral and perfectly symmetrical parkinsonism
Early dystonia
Clinical profile suggestive of behavioral variant frontotemporal dementia (bvFTD)
Progressive aphasia or apraxia
Moderate or severe postural instability and / or early falls
Early bulbar dysfunction (dysarthria, swallowing disorders)
Ventilatory dysfunction (inspiration)
Severe dysautonomia
Neuroleptic treatment or related
Normal MIBG myocardial scintigraphy (if performed)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note